Home> Products> onceyearly infusion

{ "products": [ { "_id": "6a460bf90c11f3c74a816c87", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "methylprednisolone sodium succinate for injection usp", "description": "Methylprednisolone Sodium Succinate for Injection USP is a fast-acting corticosteroid administered intravenously or intramuscularly to control severe inflammation, allergic reactions, and autoimmune flare-ups. It works by rapidly suppressing the immune and inflammatory response and is used in hospital or clinical settings for acute conditions such as severe asthma attacks, anaphylaxis, autoimmune disease flares, and spinal cord injury protocols. It is a Schedule H prescription drug administered only under medical supervision.\n\nWhat Is Methylprednisolone Sodium Succinate for Injection USP?\n\nMethylprednisolone Sodium Succinate for Injection USP is a water-soluble, injectable corticosteroid used for rapid control of severe inflammatory, allergic, and autoimmune conditions. It is manufactured to United States Pharmacopeia (USP) standards and is typically administered by a healthcare professional via intravenous (IV) or intramuscular (IM) route when fast, high-potency anti-inflammatory or immunosuppressive action is required — situations where oral steroids act too slowly or oral intake isn't feasible.\n\nHow It Works\n\nMethylprednisolone sodium succinate is a synthetic glucocorticoid that acts rapidly once reconstituted and injected.\n\n\nBinds glucocorticoid receptors – enters cells and binds intracellular receptors that regulate inflammatory gene expression.\nSuppresses inflammatory mediators – reduces production of prostaglandins, leukotrienes, and cytokines responsible for swelling, redness, and pain.\nStabilizes cell membranes – reduces capillary permeability, limiting fluid leakage and tissue swelling at the site of inflammation.\nDampens immune overactivity – suppresses lymphocyte and macrophage activity, calming autoimmune or allergic overreactions.\nDelivers rapid systemic action – because it's water-soluble and given IV/IM, onset of anti-inflammatory effect is significantly faster than oral steroids.\n\n\nClinical Indications\n\nConditionWhy Methylprednisolone Injection Is UsedSevere Allergic Reactions / AnaphylaxisRapidly controls swelling, airway inflammation, and allergic cascadeAcute Asthma Exacerbation / COPD FlareReduces airway inflammation when inhalers alone are insufficientAutoimmune Disease Flares (Lupus, Rheumatoid Arthritis)High-dose pulse therapy to control acute flaresSpinal Cord Injury (acute, under specialist protocol)Used in specific clinical protocols to limit secondary inflammationSevere Dermatologic ReactionsControls widespread inflammatory skin reactionsPost-Transplant / Organ Rejection ManagementUsed as part of immunosuppressive regimens\n\nDosage & Administration\n\nParameterRecommendationTypical Adult Dose10–40 mg IV, may range up to 30 mg/kg in high-dose pulse therapy for specific conditionsRouteIntravenous (IV) injection/infusion or Intramuscular (IM) injectionFrequencyAs directed by the treating physician; often single dose or short tapering courseReconstitutionMust be reconstituted only with the accompanying diluent as per product insert, immediately before useAdministration SettingHospital, clinic, or under direct medical/nursing supervision onlyDurationShort-term acute use unless otherwise directed; long-term use requires specialist monitoring\n\nThis is a Schedule H prescription-only medicine. Dosage must be determined and administered by a qualified healthcare professional.\n\nPrecautions\n\n\nTo be administered only by or under the supervision of a healthcare professional.\nNot for self-administration or home use.\nInform the doctor of any active infections, as corticosteroids can mask symptoms and suppress immune response.\nUse with caution in patients with diabetes, hypertension, peptic ulcer disease, osteoporosis, or psychiatric history.\nAvoid live vaccines during treatment due to immunosuppressive effects.\nPregnant or breastfeeding patients should use only under strict medical guidance.\nAbrupt discontinuation after prolonged use should be avoided; tapering may be required as advised by the physician.\n\n\nPossible Side Effects\n\nMost side effects relate to the drug's systemic corticosteroid action and are monitored by the administering clinician:\n\n\nElevated blood sugar levels\nFluid retention, increased blood pressure\nMood changes, insomnia, or restlessness\nNausea or gastrointestinal discomfort\nIncreased susceptibility to infection\nInjection site reactions\n\n\nSerious side effects requiring immediate medical attention include severe allergic reaction, signs of infection (fever, chills), significant mood or behavioral changes, unusual swelling, or vision disturbances. Because this is administered in a clinical setting, the healthcare team monitors for these actively.\n\nComparison: Methylprednisolone vs. Other Injectable Corticosteroids\n\nDrugRelative PotencyCommon Use CaseRouteMethylprednisolone Sodium SuccinateHighAcute severe inflammation, autoimmune flaresIV/IMHydrocortisone Sodium SuccinateLowerAdrenal insufficiency, milder acute inflammationIV/IMDexamethasone Sodium PhosphateVery HighCerebral edema, severe allergic/inflammatory conditionsIV/IMBetamethasone Sodium PhosphateHighAllergic and inflammatory conditions, fetal lung maturityIV/IMTriamcinolone AcetonideModerate (depot)Localized/intra-articular inflammationIM/Intra-articular\n\nKey Statistics\n\nStatisticData PointSourceOnset of anti-inflammatory action after IV administrationWithin 1–2 hours for measurable effectClinical pharmacology references, USP monographUse in acute severe asthma protocolsRecommended as part of systemic corticosteroid therapy in emergency guidelinesGlobal Initiative for Asthma (GINA) guidelinesHospital use in anaphylaxis managementIncluded as an adjunct in anaphylaxis treatment protocols alongside epinephrineWorld Allergy Organization guidanceHigh-dose pulse therapy applicationUsed in select autoimmune flare protocols under specialist supervisionPublished rheumatology treatment guidelines\n\nExpert Insight\n\n[Insert verified physician or clinical pharmacologist commentary here — Claude has not fabricated a quote. Recommend sourcing a short, attributable statement from a Steris Healthcare medical advisor or a cited clinical guideline before publishing.]\n\nConclusion\n\nMethylprednisolone Sodium Succinate for Injection USP is a high-potency, fast-acting corticosteroid reserved for situations where rapid control of severe inflammation, allergic reaction, or autoimmune flare is essential. Administered only under clinical supervision, it plays a critical role in emergency and hospital-based treatment protocols — from anaphylaxis and acute asthma to autoimmune disease management. As a Schedule H medicine, it must never be self-administered; dosage, route, and duration should always be determined by a qualified physician based on the patient's condition. For pharmacopoeia-grade quality and reliable hospital supply, source this injection through a WHO-GMP certified manufacturer.\n\nPrescription only – consult your doctor.\n\n\nHigh-Ranking FAQs (Google Search & Voice Search Optimized)\n\n1. What is methylprednisolone sodium succinate injection used for?\nIt is used to rapidly control severe inflammation, allergic reactions, and autoimmune flare-ups, such as anaphylaxis, acute asthma attacks, and lupus or rheumatoid arthritis flares. It is administered under medical supervision in hospital or clinical settings.\n\n2. Is methylprednisolone injection a steroid?\nYes, it is a synthetic corticosteroid (glucocorticoid) that works by suppressing inflammatory and immune responses in the body, providing rapid relief in acute, severe conditions.\n\n3. How is methylprednisolone sodium succinate injection given?\nIt is given by a healthcare professional via intravenous (IV) or intramuscular (IM) injection, after being reconstituted with the correct diluent immediately before administration. It is not for self-injection or home use.\n\n4. How fast does methylprednisolone injection start working?\nBecause it is water-soluble and given directly into the bloodstream or muscle, measurable anti-inflammatory effects typically begin within one to two hours of administration.\n\n5. What are the side effects of methylprednisolone injection?\nCommon effects include elevated blood sugar, fluid retention, mood changes, and increased infection risk. These are monitored by the administering healthcare team, and serious reactions are managed promptly in a clinical setting.\n\n6. Is methylprednisolone sodium succinate injection available without a prescription?\nNo. It is a Schedule H prescription-only medicine that must be administered by or under the direct supervision of a qualified healthcare professional.\n\n7. What is the difference between methylprednisolone and dexamethasone injection?\nBoth are injectable corticosteroids, but dexamethasone has a longer duration of action and higher relative potency, while methylprednisolone is often preferred for acute pulse therapy and shorter-acting systemic control. The choice depends on the clinical scenario and physician judgment.\n\n8. Can methylprednisolone injection be used in pregnancy?\nIt may be used in pregnancy only when clearly necessary and under strict medical supervision, as the treating physician will weigh the benefits against potential risks for the specific condition being treated.", "price": 47.0, "discountamount": 19.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2465, "imageuri": "https://productimages.withfloats.com/actual/6a460bfb9f5529389b8b15b8.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a460bfb9f5529389b8b15b8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-07-02T06:58:01.631Z", "updatedon": "2026-07-02T06:58:01.631Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/methylprednisolone-sodium-succinate-for-injection-usp/2465", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "METHIDENOSOLE 40 INJ", "category": "GENERAL RANGE", "tags": [ "methylprednisolone sodium succinate injection uses", "methylprednisolone sodium succinate injection uses in hindi", "methylprednisolone sodium succinate", "methylprednisolone sodium succinate injection", "inj methylprednisolone sodium succinate", "methylprednisolone sodium succinate uses in hindi", "methylprednisolone sodium succinate for injection", "methylprednisolone sodium succinate injection usp" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "699990a8814d89cb6a29a9c8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ferric carboxymaltose injection", "description": "RUDIX FCM IV is a sterile intravenous iron formulation containing Ferric carboxymaltose, designed for the rapid and effective treatment of iron deficiency and iron deficiency anemia (IDA). It is specifically developed for patients who require fast iron replenishment, cannot tolerate oral iron supplements, or have conditions where oral iron therapy is ineffective.\n\nIron deficiency remains one of the most common nutritional deficiencies worldwide, affecting women, children, patients with chronic diseases, and individuals recovering from surgery. RUDIX FCM IV provides a modern, safe, and convenient approach to restoring iron stores efficiently under medical supervision.\n\nProduct Overview\n\nProduct Name: RUDIX FCM IV\n\nGeneric Name: Ferric Carboxymaltose Injection\n\nDosage Form: Intravenous injection / infusion\n\nRoute of Administration: IV use only\n\nIndication: Treatment of iron deficiency and iron deficiency anemia\n\nRUDIX FCM IV is formulated using advanced iron-carbohydrate complex technology that allows controlled and gradual release of iron into the bloodstream. This reduces the risk of free iron toxicity while ensuring effective replenishment of hemoglobin levels and iron stores.\n\nWhat is Ferric Carboxymaltose?\n\nFerric carboxymaltose is a next-generation intravenous iron complex. Unlike traditional iron salts, it allows the administration of larger single doses in a shorter duration, reducing the need for multiple hospital visits. The iron core is tightly bound within a carbohydrate shell, enabling controlled release and minimizing adverse reactions compared to older IV iron formulations.\n\nOnce administered, iron from ferric carboxymaltose is taken up by the body's iron-binding proteins and transported to the bone marrow, where it supports red blood cell production and improves hemoglobin levels.\n\nUses of RUDIX FCM IV\n\nRUDIX FCM IV is indicated in the following medical conditions:\n\n1. Iron Deficiency Anemia (IDA)\n\nUsed when oral iron therapy is ineffective, poorly tolerated, or when rapid correction of anemia is required.\n\n2. Chronic Kidney Disease (CKD)\n\nPatients with CKD often experience anemia due to reduced erythropoietin production and iron deficiency. IV iron helps restore iron levels efficiently.\n\n3. Postpartum Anemia\n\nWomen who experience significant blood loss during childbirth may require quick iron restoration.\n\n4. Heavy Menstrual Bleeding\n\nFor women with chronic blood loss leading to iron deficiency.\n\n5. Gastrointestinal Disorders\n\nConditions such as inflammatory bowel disease (IBD), celiac disease, or gastric surgery can impair iron absorption, making IV iron therapy necessary.\n\n6. Pre- and Post-Surgical Patients\n\nPatients undergoing major surgeries may require rapid iron replenishment to improve recovery.\n\nKey Benefits of RUDIX FCM IV\n✔ Rapid Iron Replenishment\n\nAllows administration of high doses in a single sitting, helping patients recover faster compared to oral supplements.\n\n✔ Improved Patient Compliance\n\nFewer hospital visits are required due to the ability to deliver larger doses in one infusion.\n\n✔ Better Tolerability\n\nLower incidence of gastrointestinal side effects compared to oral iron therapy.\n\n✔ Controlled Iron Release\n\nThe stable iron-carbohydrate complex reduces the risk of free iron reactions.\n\n✔ Suitable for Multiple Patient Groups\n\nSafe for use in adults with various underlying medical conditions under medical supervision.\n\n✔ Clinically Proven Effectiveness\n\nHelps improve hemoglobin levels, replenish iron stores, and reduce fatigue and weakness associated with anemia.\n\nDosage and Administration\n\nRUDIX FCM IV should be administered only by qualified healthcare professionals in a clinical setting. The dosage depends on:\n\nPatient’s body weight\n\nHemoglobin level\n\nSeverity of iron deficiency\n\nUnderlying medical condition\n\nIt may be given as a slow intravenous injection or diluted in saline for infusion. Monitoring during and after administration is recommended to ensure patient safety.\n\nPossible Side Effects\n\nLike all medications, RUDIX FCM IV may cause side effects, although not everyone experiences them.\n\nCommon Side Effects:\n\nHeadache\n\nNausea\n\nDizziness\n\nInjection site reactions\n\nFlushing\n\nLess Common but Serious Reactions:\n\nHypersensitivity reactions\n\nHypotension (low blood pressure)\n\nAllergic reactions\n\nShortness of breath\n\nPatients should be monitored during infusion. Immediate medical attention is required if signs of severe allergic reactions occur.\n\nPrecautions and Warnings\n\nShould not be used in patients with known hypersensitivity to ferric carboxymaltose.\n\nNot recommended in patients with iron overload disorders such as hemochromatosis.\n\nUse cautiously in patients with liver dysfunction.\n\nPregnancy and lactation use should be evaluated by a healthcare provider.\n\nMust be administered in facilities equipped to manage anaphylactic reactions.\n\nStorage Instructions\n\nStore at controlled room temperature.\n\nProtect from light.\n\nDo not freeze.\n\nKeep out of reach of children.\n\nWhy Choose RUDIX FCM IV?\nRUDIX FCM IV stands out due to its high-quality formulation, safety profile, and effectiveness in treating iron deficiency anemia. It offers healthcare providers a reliable option for rapid correction of iron deficiency while minimizing patient inconvenience.\n\nIts ability to deliver higher doses in fewer sessions makes it a preferred choice in hospitals, nephrology clinics, gynecology practices, and surgical recovery units.\nConclusion\nIron deficiency anemia can significantly impact quality of life, causing fatigue, weakness, reduced immunity, and impaired cognitive function. Timely correction is essential to restore overall health and vitality.", "price": 2050.0, "discountamount": 615.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2310, "imageuri": "https://productimages.withfloats.com/actual/699990ae4601efddb00d005a.png", "tileimageuri": "https://productimages.withfloats.com/tile/699990ae4601efddb00d005a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-02-21T11:02:00.008Z", "updatedon": "2026-05-27T10:36:01.116Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//ferric-carboxymaltose-injection/2310", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RUDIX FCM IV", "category": "GYANECOLOGYRANGE", "tags": [ "ferric carboxymaltose injection 1000mg IV for anemia", "ferric carboxymaltose IV iron therapy dosage guide", "ferric carboxymaltose injection for iron deficiency anemia", "buy ferric carboxymaltose injection online", "ferric carboxymaltose IV injection price per vial", "ferric carboxymaltose injection 50 mg price", "ferric carboxymaltose injection price", "ferric carboxymaltose injection uses in hindi", "ferric carboxymaltose injection uses in hindi", "what is ferric carboxymaltose injection", "what is ferric carboxymaltose injection used for", "Ferric carboxymaltose injection" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "imatinib 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2026-04-15T10:27:12.329Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//imatinib-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy.", "imatinib 400mg.", "imatinib 400mg tablet.", "tab. imatinib 400mg.", "imatinib 400mg price.", "imatinib 400mg tab", "imatinib 400mg side effects.", "imatinib 400 mg tablet", "imatinib 400 mg medicine", "imatinib tablets 400 mg uses", "imatinib 400 mg dosage", "imatinib 400 mg price in india", "imatinib 400 mg brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6914248e8c1ae64991df6fc2", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Paracetamol Infusion ip", "description": "Paracetamol Infusion IP is a sterile, non-pyrogenic, and clear solution of Paracetamol (Acetaminophen) formulated for intravenous administration. It is primarily used for the management of pain and fever when oral or rectal routes are not suitable, such as in hospitalized or post-operative patients. Recognized as one of the most widely used analgesic and antipyretic medications, Paracetamol Infusion IP offers rapid onset of action, consistent therapeutic effects, and excellent patient tolerance.\n\nThis formulation ensures precise and controlled delivery of Paracetamol directly into the bloodstream, allowing for faster relief and improved bioavailability compared to oral administration.\n\nComposition\n\nEach 100 mL of Paracetamol Infusion IP typically contains:\n\nParacetamol IP – 1000 mg (1% w/v)\n\nExcipients – as required for stability and isotonicity\n\nWater for Injection – q.s. to 100 mL\n\nThe infusion is usually supplied in ready-to-use glass or plastic bottles or flexible bags, ensuring sterility and ease of use in hospital settings.\n\nMechanism of Action\n\nParacetamol (acetaminophen) exerts its therapeutic effects primarily through central inhibition of prostaglandin synthesis. Unlike nonsteroidal anti-inflammatory drugs (NSAIDs), Paracetamol has minimal peripheral anti-inflammatory activity, making it a safer option for patients with gastrointestinal or platelet-related concerns.\n\nThe drug acts by:\n\nInhibiting the cyclooxygenase (COX) enzymes, particularly COX-3, within the central nervous system, thereby reducing the synthesis of prostaglandins responsible for fever and pain.\n\nModulating the endocannabinoid system and serotonergic pathways, enhancing its analgesic potential.\n\nAs a result, Paracetamol Infusion IP provides effective fever reduction (antipyretic) and pain relief (analgesic) without significant gastrointestinal irritation or bleeding risks.\n\nIndications and Uses\n\nParacetamol Infusion IP is indicated for:\n\nManagement of Fever (Pyrexia):\n\nReduces elevated body temperature in adults and children.\n\nSuitable for patients unable to take oral medication due to nausea, vomiting, or unconsciousness.\n\nRelief of Mild to Moderate Pain:\n\nEffective in conditions like headaches, dental pain, menstrual cramps, and musculoskeletal pain.\n\nCommonly used as part of multimodal pain management after surgical procedures.\n\nPost-Operative and Trauma Pain:\n\nProvides fast, reliable pain relief in surgical recovery and trauma cases where oral medication is not feasible.\n\nAdjunct Therapy:\n\nCan be used alongside opioids to enhance analgesic effect and reduce opioid requirements.\n\nDosage and Administration\n\nAdults and adolescents (>50 kg): 1 g every 6 hours, not exceeding 4 g per day.\n\nAdults and adolescents (<50 kg): Dose adjusted based on body weight, typically 15 mg/kg every 6 hours.\n\nChildren (≥10 kg): 15 mg/kg per dose every 6 hours.\n\nThe infusion should be administered over 15 minutes, using aseptic technique. Paracetamol Infusion should not be mixed with other drugs in the same IV line unless compatibility is established.\n\nKey Benefits\n\nRapid Onset of Action:\nIntravenous administration ensures faster absorption and onset of relief compared to oral or rectal forms.\n\nHigh Bioavailability:\nSince it bypasses gastrointestinal metabolism, almost the entire dose reaches systemic circulation, providing consistent therapeutic effect.\n\nConvenience in Critical Care:\nIdeal for patients who are unconscious, post-surgery, or unable to tolerate oral medications.\n\nSafe and Well-Tolerated:\nHas minimal gastrointestinal side effects and no significant effect on platelets or renal function when used within the recommended dose range.\n\nEffective Multimodal Pain Relief:\nEnhances pain control when combined with opioids, allowing reduced opioid dosage and minimizing associated risks.\n\nStable Formulation:\nThe isotonic and sterile composition ensures patient safety, stability, and reduced risk of contamination.\n\nSuitable for Broad Patient Demographics:\nCan be used in adults, elderly patients, and children under proper medical supervision.\n\nPrecautions and Warnings\n\nWhile Paracetamol Infusion IP is generally safe, the following precautions should be observed:\n\nLiver Impairment:\nUse with caution in patients with hepatic insufficiency, chronic alcoholism, or pre-existing liver disease, as Paracetamol is primarily metabolized in the liver.\n\nRenal Impairment:\nDosage adjustment may be required in severe renal dysfunction.\n\nAvoid Overdose:\nExceeding the recommended dose can lead to severe liver toxicity and, in extreme cases, hepatic failure.\n\nDrug Interactions:\nConcomitant use with other Paracetamol-containing medications increases risk of overdose.\nCaution when used with hepatotoxic drugs or alcohol.\n\nPregnancy and Lactation:\nGenerally considered safe when used under medical supervision, though benefits should outweigh potential risks.\n\nPossible Side Effects\n\nAlthough rare and usually mild, Paracetamol Infusion IP may cause:\n\nAllergic Reactions:\nSkin rash, itching, urticaria, or swelling.\n\nHypotension:\nA transient drop in blood pressure may occur during infusion in some patients.\n\nLiver Toxicity:\nOverdose or prolonged use can lead to hepatocellular injury or elevated liver enzymes.\n\nInjection Site Reactions:\nMild pain, redness, or inflammation at the infusion site.\n\nBlood Disorders (Very Rare):\nThrombocytopenia or leukopenia may occur in extremely rare cases.\n\nIf any severe reaction such as jaundice, persistent vomiting, or allergic swelling occurs, medical attention should be sought immediately.\n\nStorage and Handling\n\nStore below 30°C, protected from light and freezing.\n\nDo not use if the solution appears cloudy or contains particles.\n\nSingle-use only; discard any unused portion after opening.\n\nConclusion\n\nParacetamol Infusion IP stands as a trusted, fast-acting, and safe intravenous formulation of one of the most widely used analgesic and antipyretic agents worldwide. Its ability to deliver rapid and predictable pain and fever relief makes it invaluable in hospitals, emergency care, and post-surgical settings.\n\nWith its favorable safety profile, high efficacy, and compatibility with multimodal pain management strategies, Paracetamol Infusion IP continues to be a first-line choice for clinicians seeking a reliable and well-tolerated solution for pain and fever management.", "price": 225.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2200, "imageuri": "https://productimages.withfloats.com/actual/6914248ff448eb2e5cf3b164.png", "tileimageuri": "https://productimages.withfloats.com/tile/6914248ff448eb2e5cf3b164.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-12T06:09:18.258Z", "updatedon": "2026-03-13T12:40:23.431Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//paracetamol-infusion-ip/2200", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "METAPECT 1% W/V ", "category": "GENERAL RANGE", "tags": [ "paracetamol infusion ip", "paracetamol infusion injection ip", "paracetamol iv infusion ip", "paracetamol infusion 100 ml ip", "paracetamol infusion for fever ip", "paracetamol infusion uses", "paracetamol infusion indications", "paracetamol iv infusion for pain relief", "paracetamol infusion for high fever", "paracetamol infusion side effects", "paracetamol iv infusion adverse effects", "paracetamol infusion precautions", "is paracetamol infusion safe", "what is paracetamol infusion used for", "when is paracetamol infusion given", "paracetamol infusion vs injection difference", "how long does paracetamol iv infusion take", "can paracetamol infusion be given to children" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6822f6b2ab5024c71f211f50", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "zoledronic acid injection", "description": "ZOLMIGRAN is a powerful intravenous medication containing Zoledronic Acid 5mg, designed to treat and prevent bone-related complications in various conditions such as osteoporosis, Paget’s disease of bone, and cancers that affect bones. It belongs to a class of drugs known as bisphosphonates, which help in strengthening bones, reducing bone loss, and preventing fractures. ZOLMIGRAN is often recommended when oral treatments are ineffective or not well-tolerated.\n\nKey Ingredients\nZoledronic Acid (5mg): The active pharmaceutical ingredient responsible for inhibiting bone resorption and maintaining bone density.\n\nKey Benefits\nHelps in the treatment of osteoporosis in postmenopausal women and men at high risk of fractures.\n\nEffective in treating Paget's disease of bone, promoting normal bone formation.\n\nReduces the risk of bone fractures in patients with cancer that has spread to bones.\n\nPrevents skeletal-related events (SREs) like bone pain, fractures, and spinal cord compression in metastatic bone diseases.\n\nOffers a once-yearly infusion for osteoporosis, improving patient compliance.\n\nHow Does It Work?\nZOLMIGRAN works by binding strongly to the bone surface, specifically at sites of active resorption. Zoledronic Acid inhibits the activity of osteoclasts, the cells responsible for breaking down bone tissue. By reducing osteoclast activity, it slows down the process of bone resorption, leading to increased bone mass and strength. This action helps in stabilizing bone structure, reducing the likelihood of fractures and other bone complications.\n\nDirections for Use\nZOLMIGRAN is administered as an intravenous infusion by a healthcare professional.\n\nThe usual dosage for osteoporosis is a single 5mg infusion once a year.\n\nFor Paget's disease of bone, a single 5mg infusion is typically sufficient.\n\nAdequate hydration before and after the infusion is recommended.\n\nCalcium and vitamin D supplementation may be prescribed to support bone health.\n\nFollow your doctor’s specific instructions regarding dosage and frequency.\n\nSide Effects\nCommon side effects include flu-like symptoms such as fever, chills, muscle pain, and joint pain after infusion.\n\nMay cause headache, fatigue, and nausea.\n\nCan lead to low blood calcium levels (hypocalcemia), which may require supplementation.\n\nPossible kidney function impairment, especially in patients with pre-existing conditions.\n\nRarely, osteonecrosis of the jaw (ONJ) and atypical femur fractures can occur with long-term use.\n\nAlways inform your doctor of any side effects experienced post-infusion.", "price": 3500.0, "discountamount": 1050.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "require supplementation", "recommended calcium", "usual dosage", "high risk", "jaw onj", "headache fatigue", "flulike symptoms", "healthcare professional", "action helps", "cells responsible", "binding strongly", "onceyearly infusion", "postmenopausal women", "oral treatments", "affect bones", "fractures effective", "bone tissue", "joint pain", "intravenous infusion", "bone fractures", "pagets disease", "osteoporosis pagets disease", "bone pain fractures", "preventing fractures zolmigran", "single 5mg infusion", "reducing osteoclast activity", "treating pagets disease", "atypical femur fractures", "work zolmigran works", "bone complications directions", "increased bone mass", "bone resorption leading", "bone surface specifically", "inhibiting bone resorption", "powerful intravenous medication", "kidney function impairment", "doctors specific instructions", "spinal cord compression", "prevent bonerelated complications" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2110, "imageuri": "https://productimages.withfloats.com/actual/6822f6b37108c6234142be46.png", "tileimageuri": "https://productimages.withfloats.com/tile/6822f6b37108c6234142be46.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-13T07:37:22.447Z", "updatedon": "2026-03-16T06:23:41.397Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//zoledronic-acid-injection/2110", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ZOLMIGRAN", "category": "ORTHOLOGYRANG", "tags": [ "Zoledronic acid Injection cost", "Zoledronic acid Injection dose", "Zoledronic acid Injection price", "Zoledronic acid infusion protocol", "Zoledronic Acid Injection price in India", "Zoledronic acid injection uses" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66d999cc236afd258ed10348", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nintedanib 100 mg", "description": "NINTEDONE 100 \nNintedanib 100 mg is a cutting-edge oral medication designed to combat progressive lung conditions and certain cancers, offering hope to patients facing debilitating fibrotic diseases. As a small-molecule tyrosine kinase inhibitor, it targets key pathways involved in abnormal cell growth and tissue scarring, making it a vital therapy for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrosing interstitial lung diseases (PF-ILD). Manufactured to high standards, this formulation delivers precise dosing in a convenient capsule form, ensuring consistent absorption and efficacy for long-term management.​\n\nUses of Nintedanib 100 mg\nNintedanib 100 mg stands out for its approved indications in slowing the decline of lung function in adults with IPF, a chronic and fatal lung disease characterized by progressive scarring of lung tissue. It is also indicated for SSc-ILD, where it helps manage lung fibrosis associated with systemic sclerosis, and PF-ILD, covering other chronic fibrosing lung conditions with a progressive phenotype. Beyond pulmonary fibrosis, Nintedanib has shown utility in oncology, particularly when combined with docetaxel for second-line treatment of advanced non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology, inhibiting tumor angiogenesis and growth.​\n\nThis medication addresses the underlying fibrotic processes by restricting fibroblast proliferation and migration, which are central to lung tissue damage. In clinical practice, physicians prescribe Nintedanib 100 mg for patients with confirmed diagnoses via high-resolution CT scans or lung biopsies, often after other treatments fail. Its versatility extends to off-label considerations in other cancers like pancreatic or colorectal, though primary use remains in respiratory fibrosis and lung cancer, providing a targeted approach where traditional therapies fall short.​\n\nKey Benefits of Nintedanib 100 mg\nOne of the primary benefits of Nintedanib 100 mg is its proven ability to reduce the rate of forced vital capacity (FVC) decline, a key measure of lung function, by up to 50% in IPF patients compared to placebo in landmark trials. This translates to slower disease progression, fewer acute exacerbations, and improved quality of life, allowing patients to maintain daily activities longer. The oral administration enhances patient compliance, avoiding the need for infusions or hospital visits.​\n\nSlows Fibrosis Progression: By inhibiting multiple tyrosine kinases, it curbs excessive scar tissue formation in the lungs, preserving respiratory capacity over time.​\n\nAnti-Angiogenic Effects: In cancer settings, it blocks vascular endothelial growth factor receptors (VEGFR), reducing tumor blood supply and metastasis risk.​\n\nBroad-Spectrum Kinase Inhibition: Targets fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and others, addressing multifaceted disease pathways.​\n\nManageable Long-Term Use: Clinical data supports sustained benefits with dose adjustments, minimizing hospitalizations for respiratory failure.​\n\nImproved Survival Metrics: In combination therapies for NSCLC, it extends progression-free survival, offering valuable time for patients.​\n\nThese advantages make Nintedanib 100 mg a cornerstone in modern pulmonology and oncology, backed by phase III trials demonstrating statistically significant outcomes in diverse patient populations.​\n\nSide Effects of Nintedanib 100 mg\nWhile effective, Nintedanib 100 mg can cause gastrointestinal side effects as the most common issue, affecting over 60% of users primarily due to its impact on kinase signaling in the gut. Diarrhea often starts within the first two weeks and is typically manageable with dose reduction or antidiarrheal agents like loperamide. Other frequent effects include nausea, vomiting, and decreased appetite, which may lead to weight loss if not addressed.​\n\nMore serious side effects warrant close monitoring:\n\nLiver Enzyme Elevations: Hepatotoxicity occurs in about 10-15% of patients, necessitating monthly liver function tests, especially in those with pre-existing liver conditions.​\n\nCardiovascular Risks: Potential for arterial thromboembolism or hypertension; baseline cardiac evaluation is recommended.​\n\nBleeding Events: Due to VEGF inhibition, minor bleeding like epistaxis is common, but gastrointestinal hemorrhage requires immediate attention.​\n\nRare but Severe: Interstitial lung disease progression (paradoxical worsening), perforations, or severe infections in immunocompromised patients.​\n\nPatients should report persistent diarrhea, abdominal pain, jaundice, or unusual fatigue promptly. Contraindications include pregnancy (category D), active bleeding, or hypersensitivity, with strong recommendations against use in moderate to severe hepatic impairment.​\n\nDosage and Administration Insights\nTypically initiated at 150 mg twice daily for IPF and ILD, Nintedanib 100 mg allows for flexible dosing—starting lower at 100 mg BID if tolerated poorly, with food to reduce GI upset. For NSCLC, it's 200 mg BID with docetaxel cycles. Regular monitoring every 2-3 months adjusts for tolerance, emphasizing adherence to slow disease modification.​\n\nConclusion\nNintedanib 100 mg represents a breakthrough in managing progressive fibrotic lung diseases and select cancers, delivering targeted inhibition of fibrotic and angiogenic pathways for tangible clinical benefits. Its ability to slow FVC decline, enhance patient quality of life, and integrate into combination regimens underscores its value, despite manageable side effects like diarrhea that respond well to supportive care. For those battling IPF, SSc-ILD, or NSCLC, Nintedanib 100 mg offers a proactive defense against relentless progression, empowering longer, more active lives under specialist guidance.​", "price": 795.0, "discountamount": 296.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one capsule", "weight loss", "scar tissue", "key players", "Key Benefits", "lung function", "initial stages", "abdominal pain", "fibrous tissue", "key ingredient", "Bleeding Events", "fibrotic tissue", "daily activities", "tyrosine kinases", "fibrotic process", "Nintedanib 100 mg", "multiple pathways", "active ingredient", "sudden worsenings", "crucial medication", "recommended dosage", "Decreased Appetite", "signaling pathways", "multiple receptors", "overall well-being", "disease progression", "acute exacerbations", "healthcare provider", "Common side effects", "elevated liver enzymes", "Gastrointestinal Issues", "other fibrotic diseases", "Liver Enzyme Elevations", "tyrosine kinase inhibitor", "progressive lung conditions", "other fibrotic lung diseases", "idiopathic pulmonary fibrosis", "potent pharmaceutical formulation", "fibroblast growth factor receptor", "platelet-derived growth factor receptor", "vascular endothelial growth factor receptor" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1971, "imageuri": "https://productimages.withfloats.com/actual/66d999d4f2036c2969cdeca8.png", "tileimageuri": "https://productimages.withfloats.com/tile/66d999d4f2036c2969cdeca8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-05T11:45:16.665Z", "updatedon": "2026-03-14T06:46:45.85Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//nintedanib-100-mg/1971", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NINTEDONE 100 ", "category": "NEPHROLOGYRANGE", "tags": [ "lung conditions and certain cancers", "Nintedanib 100 mg", "pulmonary fibrosis (IPF)", "fibrosis and lung cancer", "nintedanib 100 mg", "nintedanib capsules 100 mg", "nintedanib 100 mg capsules", "nintedanib 100 mg medicine", "nintedanib 100 mg tablet uses", "what is nintedanib 100 mg used for", "how nintedanib 100 mg works", "nintedanib 100 mg uses and benefits", "nintedanib 100 mg for lung disease", "nintedanib 100 mg for pulmonary fibrosis", "nintedanib 100 mg for idiopathic pulmonary fibrosis", "nintedanib 100 mg for interstitial lung disease", "nintedanib capsules for chronic lung disease", "nintedanib 100 mg price in india", "nintedanib 100 mg capsules price", "buy nintedanib 100 mg online", "nintedanib 100 mg supplier india", "nintedanib 100 mg manufacturer", "when should nintedanib 100 mg be taken", "who should take nintedanib 100 mg", "can nintedanib slow lung fibrosis", "how long to take nintedanib 100 mg", "does nintedanib cure pulmonary fibrosis" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662e74687f0960e14a2d95a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gefitinib 250mg", "description": "\n\nGEFISTERIS 250 is a premium pharmaceutical formulation containing Gefitinib 250mg, a breakthrough targeted therapy medication manufactured by Steris Healthcare. This innovative oral medication represents a significant advancement in the treatment of non-small cell lung cancer (NSCLC), offering patients a precise, scientifically-designed approach to combating one of the world's most challenging malignancies. GEFISTERIS 250 is specifically engineered to target the underlying molecular mechanisms that drive certain types of lung cancer, providing hope and extended survival for patients who carry specific genetic mutations.\nAs a tyrosine kinase inhibitor, GEFISTERIS 250 works at the cellular level to interrupt the signals that tell cancer cells to grow and divide. This targeted approach differs fundamentally from traditional chemotherapy, which affects both healthy and cancerous cells. By focusing specifically on cancer cells with epidermal growth factor receptor (EGFR) mutations, GEFISTERIS 250 offers a more refined treatment strategy with potentially fewer systemic side effects and improved quality of life during treatment.\nUnderstanding Gefitinib 250mg: The Science Behind GEFISTERIS 250\nGefitinib 250mg, the active pharmaceutical ingredient in GEFISTERIS 250, belongs to a revolutionary class of medications known as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The development of this medication marked a paradigm shift in oncology, moving from one-size-fits-all chemotherapy approaches to personalized, mutation-specific treatments.\nThe EGFR protein is found on the surface of cells and plays a crucial role in cell growth and division. In normal cells, EGFR activation is carefully regulated. However, in certain lung cancers, mutations in the EGFR gene cause the receptor to remain constantly active, sending continuous signals for the cell to grow, divide, and survive—leading to uncontrolled cancer growth. GEFISTERIS 250 works by blocking the tyrosine kinase activity of the mutated EGFR protein, effectively turning off the growth signal and causing cancer cells to stop proliferating and eventually die.\nThis precision targeting is what makes GEFISTERIS 250 particularly effective for patients whose tumors harbor activating EGFR mutations, particularly the common exon 19 deletions or exon 21 L858R substitution mutations. Before initiating treatment with GEFISTERIS 250, patients undergo molecular testing to confirm the presence of these mutations, ensuring that the therapy is appropriately matched to their specific cancer biology.\nPrimary Uses and Indications of GEFISTERIS 250\nGEFISTERIS 250 is primarily indicated for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors have specific EGFR mutations. The medication is approved for both first-line treatment in newly diagnosed patients and for those whose disease has progressed after platinum-based chemotherapy.\nFirst-Line Treatment: When EGFR mutations are detected in treatment-naïve patients, GEFISTERIS 250 offers an excellent first-line option, often providing superior progression-free survival compared to traditional chemotherapy regimens. Patients starting with targeted therapy typically experience better tolerability and quality of life during initial treatment phases.\nSecond-Line and Beyond: For patients whose cancer has progressed after chemotherapy, GEFISTERIS 250 provides an effective alternative treatment option, particularly when EGFR mutation testing was not performed initially or when the mutation status was unknown at the time of first treatment.\nThe medication is taken orally as a once-daily tablet, offering significant convenience compared to intravenous chemotherapy that requires hospital visits and lengthy infusion times. This oral administration allows patients to maintain greater independence and normalcy in their daily lives while receiving effective cancer treatment.\nKey Benefits of GEFISTERIS 250\n1. Targeted Cancer Fighting Action\nThe primary benefit of GEFISTERIS 250 lies in its precision targeting mechanism. Unlike conventional chemotherapy that attacks all rapidly dividing cells in the body, GEFISTERIS 250 specifically targets cancer cells bearing EGFR mutations. This selective action means that healthy cells are largely spared, resulting in a more favorable side effect profile and better preservation of normal bodily functions during treatment.\n2. Superior Efficacy in EGFR-Mutant NSCLC\nClinical trials have consistently demonstrated that GEFISTERIS 250 and other EGFR-TKIs provide superior progression-free survival compared to chemotherapy in patients with EGFR-mutant NSCLC. Response rates typically range from 60-80% in appropriate patient populations, with many patients experiencing significant tumor shrinkage and symptomatic improvement within weeks of starting treatment.\n3. Improved Quality of Life\nPatients taking GEFISTERIS 250 often report better quality of life compared to those receiving traditional chemotherapy. The medication's targeted nature results in fewer debilitating side effects such as severe nausea, hair loss, and profound fatigue. Many patients can continue working, traveling, and engaging in normal daily activities while on treatment.\n4. Convenient Oral Administration\nGEFISTERIS 250's once-daily oral dosing eliminates the need for frequent hospital visits for intravenous chemotherapy infusions. Patients take one tablet daily at home, providing tremendous convenience and reducing the burden of treatment. This ease of administration contributes significantly to treatment adherence and patient satisfaction.\n5. Rapid Symptom Relief\nMany patients experience rapid improvement in cancer-related symptoms such as cough, shortness of breath, chest pain, and fatigue within the first few weeks of GEFISTERIS 250 treatment. This quick symptomatic relief can dramatically improve quality of life even before significant tumor shrinkage is visible on imaging studies.\n6. Extended Survival Benefits\nLong-term data demonstrates that appropriate use of EGFR-TKIs like GEFISTERIS 250 contributes to extended overall survival in patients with EGFR-mutant lung cancer. When used as part of a comprehensive treatment strategy, including potential sequential therapies after progression, patients can achieve survival times that were unimaginable before the advent of targeted therapies.\n7. Manageable Side Effect Profile\nWhile GEFISTERIS 250 does cause side effects, they are generally more manageable than those associated with traditional chemotherapy. Most side effects can be effectively controlled with supportive medications, dose modifications, or temporary treatment interruptions, allowing patients to continue benefiting from therapy.\n8. Quality Manufacturing by Steris Healthcare\nGEFISTERIS 250 benefits from Steris Healthcare's commitment to pharmaceutical excellence. Each tablet undergoes rigorous quality testing to ensure consistent potency, purity, and bioavailability. This quality assurance means patients receive reliable, effective medication with every dose.\nSide Effects of GEFISTERIS 250 (Gefitinib 250mg)\nWhile GEFISTERIS 250 offers significant therapeutic benefits, patients should be aware of potential side effects. Understanding these effects enables early recognition and appropriate management.\nCommon Side Effects (Affecting 20% or More of Patients):\nSkin Reactions: The most characteristic side effect of GEFISTERIS 250 is an acne-like rash, typically appearing on the face, chest, and back within the first few weeks of treatment. This rash, while cosmetically concerning for some patients, actually correlates with better treatment response. The rash can be managed with topical antibiotics, moisturizers, and sun protection. In severe cases, temporary dose reduction may be necessary.\nDiarrhea: Approximately 50-60% of patients experience diarrhea of varying severity. Mild diarrhea can often be managed with dietary modifications and over-the-counter anti-diarrheal medications like loperamide. Patients should stay well-hydrated and contact their healthcare provider if diarrhea becomes severe or persistent, as dose adjustments may be needed.\nNail Changes: Some patients develop paronychia (nail bed inflammation) or other nail abnormalities. Proper nail care, avoiding trauma to the nail beds, and wearing protective gloves during housework can help minimize these effects.\nDry Skin: Many patients experience skin dryness and itching. Regular use of fragrance-free moisturizers, gentle cleansers, and avoidance of hot showers can help manage these symptoms.\nMouth Sores: Oral mucositis or stomatitis can develop in some patients. Good oral hygiene, avoiding spicy or acidic foods, and using alcohol-free mouthwashes can provide relief.\nLess Common but Serious Side Effects:\nInterstitial Lung Disease (ILD): While rare (1-2% of patients), ILD is the most serious potential side effect of GEFISTERIS 250. Symptoms include sudden onset or worsening of respiratory symptoms such as difficulty breathing, cough, or fever. This requires immediate medical attention and usually necessitates permanent discontinuation of the medication.\nLiver Function Abnormalities: Elevated liver enzymes can occur, requiring regular monitoring through blood tests. Most cases are asymptomatic and reversible with dose modification or temporary discontinuation.\nEye Problems: Dry eyes, corneal erosion, or other ocular issues may develop. Regular use of lubricating eye drops and ophthalmological evaluation when symptoms occur can prevent serious complications.\nGastrointestinal Perforation: Though rare, serious gastrointestinal complications including perforation can occur, particularly in patients with underlying GI conditions.\nManagement Strategies:\nMost side effects can be effectively managed through:\n\nProactive supportive care and prophylactic measures\nDose modifications (reduction to 250mg every other day in some cases)\nTemporary treatment interruptions allowing recovery\nSymptomatic treatment with appropriate medications\nPatient education about early recognition and reporting of symptoms\n\nPatients should maintain open communication with their healthcare team, reporting any new or worsening symptoms promptly. Regular monitoring through clinical visits and laboratory testing helps identify and address side effects before they become serious.\nDosage and Administration Guidelines\nThe standard dose of GEFISTERIS 250 is one 250mg tablet taken orally once daily, with or without food. The tablet should be swallowed whole with water and should not be crushed or chewed. If a dose is missed and it's been less than 12 hours since the scheduled time, patients should take the missed dose. If more than 12 hours have passed, skip the missed dose and resume the regular schedule—never double up on doses.\nTreatment continues until disease progression or unacceptable toxicity occurs. Some patients remain on GEFISTERIS 250 for months or even years if they continue to benefit without prohibitive side effects. Dose modifications may be necessary based on individual tolerance, typically reducing the frequency to every other day rather than lowering the individual dose.\nPrecautions and Important Considerations\nPatients taking GEFISTERIS 250 should be aware of several important precautions. The medication can cause harm to developing fetuses, so women of childbearing potential must use effective contraception during treatment and for at least two weeks after the last dose. Breastfeeding should be avoided during treatment and for two weeks after completion.\nGEFISTERIS 250 can interact with medications that affect stomach acid, including proton pump inhibitors and H2-receptor antagonists. If antacids are needed, they should be taken several hours apart from GEFISTERIS 250. The medication may also interact with certain other drugs metabolized by the liver, so patients should inform their healthcare provider about all medications, supplements, and herbal products they're taking.\nRegular monitoring is essential during GEFISTERIS 250 treatment, including periodic liver function tests, pulmonary symptom assessment, and clinical evaluation for skin and other toxicities. Patients should avoid prolonged sun exposure and use high-SPF sunscreen, as the medication can increase photosensitivity.\nConclusion\nGEFISTERIS 250 represents a transformative treatment option for patients with EGFR-mutant non-small cell lung cancer, offering targeted, effective therapy with a manageable side effect profile. Manufactured by Steris Healthcare with unwavering commitment to quality and patient outcomes, GEFISTERIS 250 delivers Gefitinib 250mg in a formulation designed for optimal bioavailability and consistent therapeutic effect.\nThe medication's precision targeting of cancer-driving mutations, combined with convenient oral administration and generally tolerable side effects, makes GEFISTERIS 250 an excellent choice for eligible patients. While side effects do occur and require monitoring and management, the potential benefits—including tumor response, symptom improvement, extended progression-free survival, and enhanced quality of life—often significantly outweigh the risks for appropriately selected patients.\nSuccess with GEFISTERIS 250 requires partnership between patients and their healthcare teams. Molecular testing to confirm EGFR mutation status before treatment, adherence to the prescribed regimen, proactive management of side effects, and regular monitoring all contribute to optimal outcomes. For many patients with EGFR-mutant lung cancer, GEFISTERIS 250 offers not just treatment, but genuine hope for extended, quality life.\nAs personalized medicine continues to evolve, medications like GEFISTERIS 250 exemplify the power of matching treatments to individual tumor characteristics. Steris Healthcare's commitment to delivering this advanced therapy with assured quality and accessibility ensures that more patients can benefit from the remarkable advances in targeted cancer treatment that Gefitinib 250mg represents.\n", "price": 2760.0, "discountamount": 828.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "food", "Call", "Uses", "Rash", "Note", "NSCLC", "Email", "nausea", "Dosage", "spread", "WhatsApp", "diarrhea", "Gefitinib", "treatment", "One tablet", "GEFISTERIS", "information", "sterispharma", "consultation", "sterisonline", "Side Effects", "cancer cells", "targeted therapy", "Regular monitoring", "healthcare provider", "small cell lung cancer", "healthcare professional", "specific EGFR mutations", "epidermal growth factor receptor", "potential liver function alterations" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1530, "imageuri": "https://productimages.withfloats.com/actual/667d25ffb56721898510e93e.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d25ffb56721898510e93e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:56:06.808Z", "updatedon": "2026-04-15T10:04:00.767Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gefitinib-250mg/1530", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GEFISTERIS 250", "category": "Oncology", "tags": [ "gefitinib 250 mg uses", "gefitinib 250 mg online purchase", "gefitinib 250 mg tablets price in india", "non-small cell lung cancer (NSCLC).", "triggered by chemotherapy.", "cancer biology.", "Superior Efficacy in EGFR-Mutant NSCLC", "gefitinib 250mg", "gefitinib 250mg tablet", "gefitinib 250mg tab", "gefitinib 250 mg tablet uses in lung cancer", "gefitinib tablets 250 mg dosage and benefits", "gefitinib 250 mg price in india", "gefitinib 250 mg EGFR inhibitor for NSCLC treatment india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662e4df2bed1f08484d7249", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Enzalutamide 160 mg Tablet", "description": "ENZULAMIDE 160\nEnzalutamide 160mg capsules represent a breakthrough in targeted therapy for advanced prostate cancer, specifically designed to inhibit androgen receptor signaling at multiple levels, slowing cancer progression even in castration-resistant cases. This oral medication, typically taken as a single daily 160mg dose (four 40mg capsules), binds directly to the androgen receptor, preventing nuclear translocation and DNA binding, which starves hormone-dependent prostate tumors of growth signals. Patients with metastatic castration-resistant prostate cancer (mCRPC), non-metastatic CRPC (nmCRPC), or metastatic castration-sensitive prostate cancer (mCSPC) benefit from its ability to delay disease advancement, reduce PSA levels, and extend progression-free survival.​\n\nAdministered continuously without cycling, enzalutamide 160mg maintains steady-state plasma levels for consistent anti-tumor activity, making it suitable for long-term management alongside standard care. Its role expands beyond initial hormone therapy failures, offering hope where traditional options falter.​\n\nProduct Uses: Targeting Advanced Prostate Cancer\nEnzalutamide 160mg primarily treats metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy or in pre-chemo settings, where tumors grow despite low testosterone. It excels in non-metastatic CRPC (nmCRPC) by delaying metastasis onset, with trials showing median metastasis-free survival exceeding 3 years versus placebo. In mCSPC, combination with ADT prolongs overall survival by months, reducing radiographic progression risks.​\n\nClinicians prescribe it for high-risk patients with rising PSA despite androgen deprivation therapy (ADT), as it shrinks tumors, alleviates bone pain from metastases, and improves quality of life metrics like urinary function and fatigue scores. Regular monitoring via PSA doubling time and imaging guides ongoing use.​\n\nKey Benefits of Enzalutamide 160mg\nEnzalutamide 160mg delivers transformative outcomes through potent androgen blockade:\n\nExtended Progression-Free Survival: PROSPER trial data indicate 97% risk reduction in metastasis or death for nmCRPC; ENZAMET shows 33% overall survival benefit in mCSPC.​\n\nPSA Response Rates: Over 78% achieve ≥50% PSA decline in mCRPC, correlating with radiographic stability and symptom palliation.​\n\nBone Metastasis Control: Lowers skeletal-related events by 30-40%, preserving mobility and reducing fracture incidence when paired with bone agents.​\n\nQuality of Life Preservation: FACT-P scores improve in pain, appetite, and emotional well-being domains, enabling patients to maintain daily activities longer.​\n\nOral Convenience: Once-daily dosing without food restrictions enhances adherence compared to infusions or multi-pill regimens.​\n\nThese advantages position enzalutamide 160mg as a cornerstone in modern prostate cancer protocols, particularly for fit patients tolerating its profile.​\n\nSide Effects: Managing Risks Effectively\nWhile effective, enzalutamide 160mg carries side effects from androgen suppression and receptor antagonism, affecting 70-90% of users to varying degrees. Most prove manageable with supportive care, dose holds, or adjustments, but vigilance remains essential.​\n\nCommon Side Effects\nFrequently reported (≥10%) issues include:\n\nFatigue/Asthenia (30-40%): Profound tiredness impacting daily tasks; rest, exercise, and stimulants like modafinil help.​\n\nHot Flashes (20-25%): Sudden heat waves; cooling strategies and SSRIs alleviate symptoms.​\n\nMusculoskeletal Pain (15-30%): Joint/muscle aches; NSAIDs or physical therapy provide relief.​\n\nDiarrhea/Constipation (10-20%): Alternating bowel changes; fiber, hydration, and laxatives balance gut function.​\n\nHypertension (10-15%): Blood pressure elevations; routine monitoring and antihypertensives control spikes.​\n\nThese transient effects often peak in first months, diminishing with acclimation.​\n\nSerious Side Effects\nSeek immediate care for:\n\nSeizures (1-2%): Risk higher with brain history; anticonvulsants or discontinuation advised.​\n\nFalls/Fractures (10-15%): Due to weakness, dizziness; fall precautions and bone density scans mitigate.​\n\nCardiovascular Events: Myocardial infarction, strokes (2-5%); lipid/BP checks essential.​\n\nPosterior Reversible Encephalopathy Syndrome (PRES): Rare confusion, seizures, vision loss; MRI confirms.​\n\nSevere Skin Reactions: Stevens-Johnson syndrome; rash monitoring critical.​\n\nBaseline neurological assessments and quarterly labs optimize safety.​\n\nDosage and Administration Guidelines\nSwallow four 40mg capsules whole once daily at the same time, with or without food, totaling 160mg. No dose reductions below 120mg recommended; hold for grade 3-4 toxicity, resuming at prior dose once resolved. Hepatic impairment (Child-Pugh B/C) warrants caution; renal adjustments unnecessary. Continue indefinitely unless progression or intolerance occurs.​\n\nPrecautions and Monitoring\nAvoid in seizure history without prophylaxis; women (especially pregnant) must not handle due to teratogenicity. Strong CYP2A4 inducers/inhibitors alter exposure—adjust accordingly. Elderly patients face amplified fall risks; annual DEXA scans track bone health. Regular PSA, testosterone, CBC, liver enzymes, and ECGs ensure proactive management.​\n\nConclusion\nEnzalutamide 160mg stands as a pivotal advancement in prostate cancer care, offering substantial delays in disease progression, symptom control, and survival gains for patients facing hormone-resistant stages. By meticulously balancing its robust benefits against manageable side effects through vigilant monitoring and supportive measures, individuals regain control over their health journey. Consult oncologists to integrate this therapy seamlessly, tailoring it to personal profiles for optimal, life-extending results\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\n\n\n\n\n\n\n\n", "price": 5531.0, "discountamount": 1660.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Call", "Email", "mCRPC", "growth", "doctor", "Dosage", "action", "fatigue", "product", "WhatsApp", "patients", "androgens", "ENZULAMIDE", "hot flashes", "information", "Enzalutamide", "sterisonline", "sterispharma", "cancer cells", "hypertension", "male hormones", "administration", "health condition", "Common side effects", "comprehensive advice", "healthcare professional", "potent anti-androgen medication", "metastatic castration-resistant prostate cancer" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1528, "imageuri": "https://productimages.withfloats.com/actual/667d2980c303c6d6ad1360bf.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d2980c303c6d6ad1360bf.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:45:51.202Z", "updatedon": "2026-03-12T07:58:25.307Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//enzalutamide-160-mg-tablet/1528", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ENZULAMIDE 160", "category": "Oncology", "tags": [ "enzalutamide 160 mg price in india", "enzalutamide 160 mg uses", "", "enzalutamide 160 mg side effects", "prostate cancer", "prostate tumors of growth signals", "metastatic castration-resistant prostate cancer", "enzalutamide 160 mg tablet uses", "enzalutamide 160 mg tablet dosage", "enzalutamide 160 mg tablet price in india", "enzalutamide 160 mg tablet composition", "enzalutamide 160 mg tablet benefits", "enzalutamide 160 mg tablet side effects", "enzalutamide 160 mg tablet how it works", "enzalutamide 160 mg tablet mechanism of action", "enzalutamide tablets 160 mg information", "enzalutamide 160 mg tablet cost", "enzalutamide 160 mg tablet supplier india", "enzalutamide 160 mg tablet manufacturer", "enzalutamide 160 mg tablet wholesale price", "enzalutamide 160 mg tablet availability in india", "what is enzalutamide 160 mg tablet", "enzalutamide 160 mg tablet treatment use", "enzalutamide 160 mg tablet precautions", "enzalutamide 160 mg tablet alternatives", "enzalutamide 160 mg tablet substitute", "enzalutamide 160 mg tablet india", "enzalutamide 160 mg tablet near me", "enzalutamide 160 mg tablet online india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662d50f8ecffe165c355141", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "capecitabine 500mg", "description": "CAPECITIME 500 \nCapecitabine lp 500mg\nCAPECITIME 500 represents a significant advancement in the landscape of oncological therapeutics. Manufactured with stringent quality standards by Steris Healthcare, this pharmaceutical product contains Capecitabine IP 500mg, a potent antimetabolite chemotherapy agent. It is designed to offer a balance of high efficacy and patient convenience, shifting the paradigm of cancer care from exclusively hospital-based intravenous treatments to a manageable, home-based oral regimen.\n\nIn the complex battle against malignancy, precision and tolerability are paramount. CAPECITABINE 500 serves as a 'prodrug'—a medication that remains largely inactive until it enters the body. Once ingested, it undergoes a unique three-step enzymatic conversion process, transforming into its active cytotoxic form, 5-fluorouracil (5-FU), preferentially within tumor tissues. This mechanism aims to maximize the destruction of cancer cells while striving to spare healthy tissues, making CAPECITABINE 500 a cornerstone therapy for patients battling colorectal, breast, and gastric cancers.\n\nMechanism of Action: The Science of CAPECITABINE 500\nUnderstanding how CAPECITIME 500 works is essential to appreciating its value. Unlike traditional chemotherapy that attacks all rapidly dividing cells indiscriminately, capecitabine is designed to be smarter.\n\nAbsorption and Conversion: Upon swallowing the CAPECITIME 500 tablet, the drug is absorbed through the intestinal wall. It passes through the liver, where it is converted into an intermediate compound.\n\nTumor Targeting: The final conversion to the active cancer-killing agent, 5-FU, occurs primarily in the presence of an enzyme called thymidine phosphorylase. Research indicates that this enzyme is often found in higher concentrations in tumor tissues compared to normal healthy tissues.\n\nDNA Disruption: Once active inside the cancer cell, the drug mimics essential nutrients the cell needs to grow (specifically inhibiting thymidylate synthase). This effectively 'starves' the cancer cell of the building blocks required for DNA replication and repair, leading to cell death (apoptosis) and slowing tumor progression.\n\nTherapeutic Indications and Uses\nCAPECITABINE 500 is a versatile oncology medication prescribed by specialists for several specific types of cancer. Its efficacy is well-documented in various clinical settings:\n\n1. Colorectal Cancer\nAdjuvant Treatment: CAPECITIME 500 is widely used for patients with Stage III (Dukes' C) colon cancer who have undergone surgery to remove the primary tumor. In this setting, the drug acts as a 'cleanup' agent, targeting any microscopic cancer cells that may remain, significantly reducing the risk of recurrence and improving survival rates.\n\nMetastatic Colorectal Cancer: For cases where the cancer has spread (metastasized) to other parts of the body, CAPECITIME 500 is often the first-line treatment. It can be used as a standalone therapy (monotherapy) or in combination with other chemotherapy agents to control disease progression.\n\n2. Breast Cancer\nAdvanced or Metastatic Disease: CAPECITIME 500 plays a critical role in treating advanced breast cancer. It is frequently prescribed when the cancer has stopped responding to other standard chemotherapy treatments, such as paclitaxel or anthracyclines.\n\nCombination Therapy: It is often paired with other drugs (e.g., docetaxel) to enhance the attack on cancer cells, providing a synergistic effect that can shrink tumors more effectively than single agents alone.\n\n3. Gastric (Stomach) Cancer\nCAPECITABINE 500 is also a key component in the treatment regimen for advanced gastric cancer, often used in combination with platinum-based chemotherapy. It helps in palliative care settings to extend survival and improve the quality of life for patients with inoperable tumors.\n\nKey Benefits of CAPECITIME 500\nPatients and healthcare providers choose CAPECITABINE 500 for several distinct advantages that set it apart from conventional intravenous chemotherapy.\n\n1. Convenience of Oral Administration\nPerhaps the most immediate benefit for the patient is the form factor. Traditional 5-FU treatment requires continuous intravenous (IV) infusion, necessitating frequent hospital visits, catheter lines, or portable pumps. CAPECITIME 500 is a tablet. This allows patients to take their medication in the comfort of their own homes, reducing hospital visits and allowing them to maintain a more normal daily routine, work schedule, and family life.\n\n2. Targeted 'Tumor-Activated' Therapy\nBecause the drug is converted to its active form largely within the tumor site (due to higher enzyme levels there), CAPECITIME 500 achieves high concentrations of medicine exactly where it is needed—inside the cancer. This targeted approach aims to reduce systemic toxicity compared to older chemotherapy methods that flood the entire bloodstream with active toxins.\n\n3. Proven Efficacy & Quality\nManufactured by Steris Healthcare, CAPECITIME 500 adheres to WHO-GMP (Good Manufacturing Practices) standards, ensuring that patients receive a product of high purity, stability, and consistent dosage. Clinical data supports that oral Capecitabine is at least equivalent to intravenous 5-FU in terms of survival outcomes for colorectal cancer, with the added benefit of improved convenience.\n\n4. Flexible Combination Partner\nCAPECITIME 500 is highly versatile. It can be effectively combined with a wide range of other cancer therapies, including radiation therapy and biologic agents, allowing oncologists to tailor treatment plans to the specific genetic makeup and stage of the patient's cancer.\n\nPotential Side Effects and Management\nWhile CAPECITIME 500 is designed to be more targeted, it is still a potent chemotherapy drug, and side effects can occur. Being aware of these helps patients manage them effectively.\n\nCommon Side Effects\nGastrointestinal Issues: Diarrhea, nausea, vomiting, and abdominal pain are common. These are usually manageable with dietary changes and additional medications prescribed by the doctor.\n\nFatigue: A general sense of tiredness or weakness is frequently reported.\n\nHand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia): This is a specific side effect where the palms of the hands and soles of the feet become red, swollen, tender, or peeled. It is caused by small amounts of the drug leaking from capillaries in these areas.\n\nSerious Side Effects (Rare but Important)\nCardiac Symptoms: Rarely, patients may experience chest pain or heart palpitations.\n\nLow Blood Cell Counts: The drug can temporarily lower the number of white blood cells (increasing infection risk), red blood cells (anemia), and platelets (bruising).\n\nSevere Diarrhea: If left untreated, this can lead to dehydration.\n\nManaging Side Effects\nHydration: Patients are advised to drink plenty of fluids.\n\nSkin Care: For Hand-Foot Syndrome, keeping hands and feet moisturized, avoiding tight shoes, and staying away from hot water/heat sources is recommended.\n\nCommunication: Early reporting of side effects to a healthcare provider often allows for dose adjustments that can stop the side effects from becoming severe.\n\nDosage and Administration\nPrescription Only: CAPECITABINE 500 is a prescription-only medicine and must be taken exactly as directed by an oncologist.\n\nTypical Cycle: A common regimen involves taking the tablets twice daily (morning and evening) for 14 consecutive days, followed by a 7-day rest period. This constitutes one 21-day cycle.\n\nWith Food: It is crucial to take CAPECITIME 500 within 30 minutes after a meal with water. Taking it with food reduces the risk of stomach upset and ensures proper absorption.\n\nConclusion\nCAPECITIME 500 (Capecitabine 500mg) stands as a vital therapeutic option in modern oncology. By combining the potency of traditional chemotherapy with the smart science of tumor-enzyme activation, it offers a powerful weapon against colorectal, breast, and gastric cancers.\n\nBeyond its chemical efficacy, CAPECITIME 500 offers the profound benefit of dignity and independence. The ability to self-administer chemotherapy at home empowers patients, reducing the burden of clinical visits and allowing them to focus more on healing and living. With its high-quality formulation by Steris Healthcare, CAPECITIME 500 provides a reliable, effective, and patient-centric solution for cancer management.", "price": 1222.0, "discountamount": 366.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "body", "Call", "blood", "Email", "class", "amount", "nausea", "doctor", "disorder", "WhatsApp", "headache", "CABERGLOW", "dizziness", "conditions", "CAPECITIME", "medication", "infertility", "information", "Capecitabine", "constipation", "instructions", "sterispharma", "sterisonline", "Cabergoline IP", "unusual symptoms", "hyperprolactinemia", "associated symptoms", "Excessive prolactin", "Common side effects", "other related issues", "normal hormone levels", "healthcare professional", "excess prolactin hormone", "dopamine receptor agonists", "irregular menstrual periods" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1525, "imageuri": "https://productimages.withfloats.com/actual/667d2be5cd6f42ac046088e1.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d2be5cd6f42ac046088e1.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T09:38:23.283Z", "updatedon": "2026-03-17T07:22:43.148Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//capecitabine-500mg/1525", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CAPECITIME 500 ", "category": "NEPHROLOGYRANGE", "tags": [ "capecitabine 500 mg tablet price", "capecitabine 500 mg tablet dosage", "capecitabine 500 mg tablet side effects", "CAPECITIME 500", "Capecitabine IP 500mg", "Combination Therapy", "CAPECITIME 500 is a tablet.", "colorectal, breast, and gastric cancers.", "CAPECITIME 500", "5-FU in terms of survival outcomes for colorectal cancer.", "capecitabine 500mg oral chemotherapy tablets", "capecitabine 500mg chemotherapy at home", "capecitabine 500mg for metastatic breast cancer", "buy capecitabine 500mg online", "capecitabine 500mg price per tablet" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }